Printer Friendly

POSSIS MEDICAL FILES INVESTIGATIONAL DEVICE EXEMPTION APPLICATION

 POSSIS MEDICAL FILES INVESTIGATIONAL DEVICE EXEMPTION APPLICATION
 MINNEAPOLIS, Sept. 14 /PRNewswire/ -- Possis Corporation (NASDAQ: POSS) announced today that Possis Medical, Inc. (PMI), its wholly owned subsidiary, has filed an Investigational Device Exemption (IDE) application with the U.S. Food and Drug Administration (FDA) for its Angiojet(TM) Thrombectomy System, a unique device initially intended for the percutaneous removal of blood clots occurring in peripheral (leg) arteries and vascular grafts. PMI plans to begin human clinical trials in the United States following IDE approval. Future Angiojet products will treat coronary artery and bypass graft thrombosis.
 The IDE application is a major step toward PMI's goal of bringing to market a family of Angiojet products designed to treat vascular thrombosis, a leading cause of death and disability, due to heart attacks, strokes, pulmonary failure and limb amputation. The Angiojet System consists of a non-disposable drive console and a disposable catheter, high-pressure pump and accessories. Angiojet produces fine saline streams from openings located in the catheter's tip to wash thrombus from the blood vessel's wall, break it into small particles, draw these particles into the catheter's tip, and propel the particles down the catheter and out of the body for disposal.
 PMI believes its Angiojet products will become important therapeutic tools for treating peripheral and coronary vascular thrombosis.
 -0- 9/14/92
 /CONTACT: Robert G. Dutcher of Possis Medical, 612-550-1010/
 (POSS) CO: Possis Corporation; Possis Medical, Inc. ST: Minnesota IN: MTC SU: PDT


AL -- MN006 -- 9112 09/14/92 11:29 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 14, 1992
Words:249
Previous Article:BI ANNOUNCES RECORD ANNUAL REVENUE; RECORD FOURTH QUARTER REVENUE
Next Article:WYLE LABORATORIES POSTS STRONG SALES AND EARNINGS GAINS TO NEW RECORD HIGHS IN SECOND QUARTER
Topics:


Related Articles
BIOPLASTY WITHDRAWS SUBMISSIONS FILED WITH FOOD AND DRUG ADMINISTRATION
POSSIS MEDICAL RECEIVES FDA APPROVAL FOR IDE APPLICATION
POSSIS MEDICAL EXPANDS ANGIOJET CLINICAL STUDY TO INCLUDE A-V ACCESS GRAFTS
POSSIS MEDICAL, INC., FILES 510(K) APPLICATION FOR PERMA-SEAL DIALYSIS ACCESS GRAFT
POSSIS MEDICAL, INC. APPLIES TO FDA FOR COMMENCEMENT OF ANGIOJET(TM) CORONARY THROMBECTOMY STUDY
POSSIS MEDICAL FILES 510(k) AND IDE APPLICATIONS AND RECEIVES SECOND U.S. PATENT FOR ANGIOJET RAPID THROMBECTOMY SYSTEM
POSSIS MEDICAL, INC. RECEIVES FDA APPROVAL FOR PHASE 2 STUDY OF ANGIOJET CORONARY THROMBECTOMY SYSTEM
Possis Medical Inc. Moves Toward U.S. Marketing Clearance For AngioJet
Possis Medical Obtains Humanitarian Designation for Its Perma-Flow Graft
Possis Medical, Inc. Seeks FDA Approval to Begin Stroke Clinical Trial with the AngioJet System

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters